Canada Markets close in 5 hrs 41 mins

Arch Biopartners Inc. (ACHFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.67000.0000 (0.00%)
As of 09:38AM EDT. Market open.

Arch Biopartners Inc.

27 Street Clair Avenue East
PO Box 305
Toronto, ON M4T 2M5

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard Gabriel MuruveCo-Founder, CEO, Pres & Director74.37kN/A1971
Dr. Daniel Abraham MuruveCo-Founder, Chief Science Officer & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Andrew Bishop CFAActing CFO & DirectorN/AN/A1966
Dr. Justin MacDonaldCo-Founder & Principal ScientistN/AN/AN/A
Dr. Paul BeckCo-Founder & Principal ScientistN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada.

Corporate Governance

Arch Biopartners Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.